Psilocybin Plus Pimavanserin Tested for Major Depressive Disorder
Bottom line: A Phase 2 trial is testing whether combining psilocybin with pimavanserin may improve outcomes for Major Depressive Disorder compared to psilocybin alone, though results are not yet available.
This trial is exploring whether adding a single antipsychotic drug to psilocybin could make psychedelic therapy for depression more predictable — and more effective.

What’s being tested
This Phase 2 trial is investigating whether combining psilocybin with pimavanserin improves outcomes for people with Major Depressive Disorder (MDD) compared to psilocybin alone. Psilocybin, a psychedelic compound found in certain mushrooms, has shown potential in altering brain activity and reducing depressive symptoms. Pimavanserin, an atypical antipsychotic, is being tested for its ability to modulate the psychedelic experience — potentially reducing side effects or increasing therapeutic benefit.
The design at a glance
The trial is currently recruiting participants and is sponsored by the Icahn School of Medicine at Mount Sinai. It is a Phase 2 study, meaning it is evaluating the effectiveness of the intervention while continuing to monitor safety in a larger group of people.
Participants will receive a single dose of either pimavanserin or a placebo, combined with a single dose of psilocybin. Assessments will be conducted before and after dosing, with follow-up evaluations up to five weeks post-dosing. The goal is to determine whether the combination therapy leads to better outcomes than psilocybin alone.
Why it matters
If successful, this trial could help refine how psilocybin is used in treating depression. Pimavanserin is a newer antipsychotic with a unique mechanism of action, and its use in combination with psilocybin might help manage some of the intense or unpredictable emotional effects that can accompany psychedelic therapy.
Understanding how these two substances work together could lead to more targeted, safer, and more effective treatments for MDD, potentially offering a new direction in mental health care.
What this does NOT mean yet
It is important to note that this is an ongoing trial and no results have been published or reported yet. Clinical trial registration does not indicate the intervention is effective or safe. Many trials do not progress beyond the early stages, and findings from this study will not be available until the trial is completed and results are peer-reviewed.
While the question being asked is scientifically interesting, the outcome remains uncertain.
How to follow it
You can track the progress of this trial through the ClinicalTrials.gov record at https://clinicaltrials.gov/study/NCT06592833. Results will be posted there once the trial is completed and data is analyzed.
Sources
https://clinicaltrials.gov/study/NCT06592833 (NCT06592833)
Educational Disclaimer
This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.
We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.
Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.
Frequently asked questions
Is combining psilocybin with pimavanserin being tested for depression treatment?
What is pimavanserin, and why is it being tested with psilocybin?
What does the trial design involve?
Are the results of this trial available yet?
How can I track the progress of this trial?
If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.